maximum weight loss tirzepatide surmount trials For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at tolerated dose. The Tirzepatide before and after: realistic

Could affect oral birth control: Since GLP-1 medications can slow digestion, they may affect how oral birth control pills are absorbed

Orforglipron is a small-molecule (non-peptide) oral GLP-1 receptor agonist

Metrics to track Beyond weight, track these metrics weekly or biweekly: Waist circumference at the navel, first thing in the morning Hip circumference at the widest point Energy level on a 1 to 10 scale Sleep quality on a 1 to 10 scale Appetite level on a 1 to 10 scale Side effects type and severity Exercise type and duration Request blood work from your provider at baseline, 12 weeks, and 24 weeks at minimum

Based on SURMOUNT-1 data, participants on the 15 mg dose were averaging roughly 15% body weight loss by around this point in the trial

In closing A short commentary today